The relevance of HBV genotype diversity on interferon (IFN) therapy outcome in chronic hepatitis B patients has recently been highlighted. Data available for genotype F is poor. The aim of this work was to analyse the response of HBV genotype F to treatment with IFN. Additionally, response was analysed according to the role of single nucleotide polymorphisms (SNPs) near to the IL28B gene.
Methods
A total of 29 HBeAg-positive patients with chronic infection were included with a median age 47 (18–68) years. Of them, 27 were male. One patient was treated with standard IFN-α for 16 weeks, 6 patients received PEG-IFN-α2a 180 mg weekly for 24 weeks and 22 patients for 48 weeks. Response to treatment was defined as loss of HBeAg, anti-HBe seroconversion and decline of HBV DNA level to below 3 log of baseline (IU/ml) at the 6-month of follow-up. The SNPs rs12979860, rs12980275 and rs8099917 were studied by PCR-RFLP.
Results
The overall response was obtained in 18 (62%) patients, including one patient who was treated with standard IFN. Additionally, a total of 9 (31%) patients cleared HBsAg, with appearance of anti-HBs. The viral load was undetectable in all of these patients. The same IL28B variants associated with IFN response in HCV infections were also more frequently found in HBV patients compared with non-responders.
Conclusions
Our study indicates that treatment with IFN is effective in patients with HBV genotype F.
References
1.
MargolisH.S.Hepatitis B virus infection.Bull World Health Organ1998; 76Suppl 2: 152–153.
2.
KaoJ.H.HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?Liver Int2014; 34Suppl 1: 112–119.
3.
SungJ.J., TsoiK.K., WongV.W.Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.Aliment Pharmacol Ther2008; 28: 1067–1077.
4.
KaoJ.H.Molecular epidemiology of hepatitis B virus.Korean J Intern Med2011; 26: 255–261.
5.
LinC.L., KaoJ.H.The clinical implications of hepatitis B virus genotype: recent advances.J Gastroenterol Hepatol2011; 26Suppl 1: 123–130.
6.
LiuC.J., KaoJ.H.Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J.Semin Liver Dis2013; 33: 97–102.
7.
FlinkH.J., van ZonneveldM., HansenB.E., de ManR.A., SchalmS.W., JanssenH.L.Treatment with peg-interferon α2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.Am J Gastroenterol2006; 101: 297–303.
8.
BoglioneL., CusatoJ., CaritiG., Di PerriG., D'AvolioA.The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon.J Infect2014; 69: 81–87.
9.
DevesaM., LoureiroC., RivasY.Subgenotype diversity of hepatitis B virus American genotype F in Amerindians from Venezuela and the general population of Colombia.J Med Virol2008; 80: 20–26.
10.
VenegasM., MuñozG., HurtadoC.Prevalence of hepatitis B virus genotypes in chronic carriers in Santiago, Chile.Arch Virol2008; 153: 2129–2132.
11.
MarcianoS., GaldameO.A., GadanoA.C.HBV genotype F: natural history and treatment.Antivir Ther2013; 18: 485–488.
12.
GeD., FellayJ., ThompsonA.J.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature2009; 461: 399–401.
13.
TanakaY., NishidaN., SugiyamaM.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.Nat Genet2009; 41: 1105–1109.
14.
VenegasM., VillanuevaR.A., GonzalezK., BrahmJ.IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients.World J Gastroenterol2011; 17: 3636–3639.
15.
European association for the study of the Liver.EASL clinical practice guidelines: management of chronic hepatitis B virus infection.J Hepatol2012; 57: 167–185.
16.
SonneveldM.J., WongV.W., WoltmanA.M.Polymorphisms Near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.Gastroenterology2012; 142: 513–520.
17.
ZhangQ., LapalusM., AsselahT.IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.J Viral Hepat2014; 21: 525–532.
